Fuming Li

Fuming Li

Auto-generated profile, based on publicly available information

Fuming Li

Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology; Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
PLPingyu Liu
Pingyu Liu
FLFuming Li
Fuming Li
JLJianhuang Lin
Jianhuang Lin
TFTakeshi Fukumoto
Takeshi Fukumoto
TNTimothy Nacarelli
Timothy Nacarelli
RZRugang Zhang
Rugang Zhang

2 January 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
FLFuming Li
Fuming Li
PLPingyu Liu
Pingyu Liu
WMWen Mi
Wen Mi
LLLiucheng Li
Liucheng Li
NANicole M. Anderson
Nicole M. Anderson
MSM. Celeste Simon
M. Celeste Simon

29 January 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZQZhen Qin
Zhen Qin
MYMeiting Yue
Meiting Yue
STShijie Tang
Shijie Tang
FWFengying Wu
Fengying Wu
HSHonghua Sun
Honghua Sun
HJHongbin Ji
Hongbin Ji
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is detectable in 5.1–7.5% of human LUAS, and transgenic expression of EML4-ALK drives lung adenocarcinoma (LUAD) formation initially and squamous transition at late stage. We identify club cells as the main cell-of-origin for squamous transition. Through recapitulating lineage transition in organoid system, we identify JAK-STAT signaling, activated by EML4-ALK phase separation, significantly promotes squamous transition. Integrative study with scRNA-seq and immunostaining identify a plastic cell subpopulation in ALK-rearranged human LUAD showing squamous biomarker expression. Moreover, those relapsed ALK-rearranged LUAD show notable upregulation of squamous biomarkers. Consistently, mouse squamous tumors or LUAD with squamous signature display certain resistance to ALK inhibitor, which can be overcome by combined JAK1/2 inhibitor treatment. This study uncovers strong plasticity of ALK-rearranged tumors in orchestrating phenotypic transition and drug resistance and proposes a potentially effective therapeutic strategy.

1 February 2021 in Neoplasia
Verified
Journal Article
Open access
ZWZuoyun Wang
Zuoyun Wang
ZFZhaoyuan Fang
Zhaoyuan Fang
GCGaobin Chen
Gaobin Chen
BLBo Liu
Bo Liu
JXJinjin Xu
Jinjin Xu
HJHongbin Ji
Hongbin Ji
Chromobox 4 (CBX4) is a core component of polycomb-repressive complex 1 with important roles in cancer biology and tissue homeostasis. Aberrant expression of CBX4 has been implicated in several human malignancies. However, its role and underlying mechanisms in the tumorigenesis of lung adenocarcinoma (LUAD) have not been defined in vivo. Here, we found that expression of CBX4 was frequently up-regulated in human LUAD samples and correlated with poor patient survival. Importantly, genetic ablation of CBX4 greatly dampened lung tumor formation and improved survival in the KrasG12D/P53L/L (KP) autochthonous mouse model of LUAD. In addition, CBX4 depletion significantly inhibited proliferation and anchorage-independent growth of KP mouse embryonic fibroblasts. Moreover, ectopic CBX4 expression clearly promoted proliferation and anchorage-independent growth in both human and mouse LUAD cells, whereas silencing of CBX4 exerted opposite effects. Mechanistically, CBX4 promoted growth of LUAD cells through activation of the Wnt/β-catenin pathway. Furthermore, expression levels of CBX4 were positively correlated with β-catenin in human LUAD samples. In conclusion, our data suggest that CBX4 plays an oncogenic role via the Wnt/β-catenin pathway and could serve as a potential therapeutic target in LUAD.

22 August 2025 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
WMWen Mi
Wen Mi
YXYun Xue
Yun Xue
HYHaohang Yan
Haohang Yan
YZYurou Zhang
Yurou Zhang
XCXinlei Cai
Xinlei Cai
FLFuming Li
Fuming Li
The energy sensor AMP-activated protein kinase (AMPK) promotes tumor cell survival under stress but how to prevent AMPK activation to blunt tumor progression remains unclear. Here we show that the metabolite α-ketoglutarate (α-KG) dictates AMPK translation through a TET–YBX1 axis, which can be exploited to sensitize human cancer cells to energy stress. α-KG-deficient cells fail to activate AMPK under glucose starvation, which elicits cytosolic NADPH depletion and disulfidptosis. Mechanistically, α-KG insufficiency inhibits TET-dependent transcription of YBX1, an RNA-binding protein required for human-specific AMPK protein synthesis. Similarly, α-KG competitors including succinate and itaconate inhibit the YBX1–AMPK axis and sensitize cancer cells to glucose deprivation. Lastly, cotargeting oncogenic YBX1 and GLUT1 creates synthetic lethality and blunts tumor growth in vivo. Together, our findings link α-KG to energy sensing through AMPK translation and propose that targeting α-KG–YBX1-dependent AMPK translation can sensitize human cancer cells to energy stress for treatment.

28 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LYLi Yang
Li Yang
JYJianwei You
Jianwei You
XYXincheng Yang
Xincheng Yang
RJRuishu Jiao
Ruishu Jiao
JXJie Xu
Jie Xu
PLPingyu Liu
Pingyu Liu
Senescence-associated secretory phenotype (SASP) mediates the biological effects of senescent cells on the tissue microenvironment and contributes to ageing-associated disease progression. ACSS2 produces acetyl-CoA from acetate and epigenetically controls gene expression through histone acetylation under various circumstances. However, whether and how ACSS2 regulates cellular senescence remains unclear. Here, we show that pharmacological inhibition and deletion of Acss2 in mice blunts SASP and abrogates the pro-tumorigenic and immune surveillance functions of senescent cells. Mechanistically, ACSS2 directly interacts with and promotes the acetylation of PAICS, a key enzyme for purine biosynthesis. The acetylation of PAICS promotes autophagy-mediated degradation of PAICS to limit purine metabolism and reduces dNTP pools for DNA repair, exacerbating cytoplasmic chromatin fragment accumulation and SASP. Altogether, our work links ACSS2-mediated local acetyl-CoA generation to purine metabolism through PAICS acetylation that dictates the functionality of SASP, and identifies ACSS2 as a potential senomorphic target to prevent senescence-associated diseases.